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Background: Somatic mutations in EGFR (exons 19 and 21) and
KRAS (exon 2) are found in lung adenocarcinomas and have poten-
tial prognostic value in patients with advanced disease. These
mutations also have therapeutic significance, as they predict for
sensitivity and resistance, respectively, to EGFR tyrosine kinase
inhibitor therapy. Whether EGFR and KRAS mutations also have an
impact on survival in patients who undergo lung resection for
curative intent in the absence of targeted therapy has not been
established.
Methods: We analyzed the clinical characteristics and outcomes
data for 296 patients who underwent resection at our institution for
stage I–III lung adenocarcinoma. Tumors were assessed for both
EGFR and KRAS mutations by established methods.
Results: EGFR and KRAS mutations were found in tumors from 40
(14%) and 50 (17%) patients, respectively. Patients with EGFR
mutant tumors were more likely to be never smokers (48%), present
with stage I disease (88%), and had a 90% (95% confidence interval
[CI] 70–97%) 3-year overall survival, whereas patients with KRAS
mutant tumors were more likely to be former/current smokers
(92%), present with locally advanced disease (40%), and had a 66%
(95% CI 48–79%) 3-year overall survival.
Conclusions: EGFR and KRAS mutations define distinct molecular
subsets of resected lung adenocarcinoma. Because EGFR and KRAS
mutations also predict whether tumors are sensitive or resistant,
respectively, to EGFR tyrosine kinase inhibitors, they can readily be
used in clinical trials to help guide the administration of specific
types of adjuvant therapy.
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Adenocarcinoma of the lung is the leading cause of cancer-related death in the United States. The incidence of the
adenocarcinoma subtype has been rising and now accounts for
50% of all cases of lung cancer.1 The overwhelming majority
of patients with lung cancer have smoked cigarettes. However,
about 10% of lung cancers arise in “never smokers”, i.e., patients
who smoked less than 100 cigarettes in a lifetime.
The introduction of epidermal growth factor receptor
(EGFR) tyrosine kinase inhibitors (TKIs) into the clinic has
led to the identification of two tumor-specific somatic muta-
tions that define clinically relevant molecular subsets of
advanced lung adenocarcinoma.2 Mutations in the kinase
domain of EGFR are more often found in never smokers and
East Asian populations. These mutations are exon 19 dele-
tions that eliminate a common leucine-arginine-glutamic
acid-alanine (LREA) motif and exon 21 point mutations that
lead to substitution of arginine for leucine at position 858.
Multiple prospective trials have demonstrated that patients
whose tumors harbor these genetic changes have a collective
response rate of nearly 75% to treatment with gefitinib or
erlotinib.3 Conversely, mutations in KRAS, which encodes a
guanosine triphosphate hydrolase (GTPase) downstream of
EGFR, are more often found in tumors from former/current
smokers and North American/European populations and
these tumors are resistant to therapy with EGFR TKI’s.4–6
These mutations lead to substitutions of amino acids for
glycines at positions 12 and 13. Tumors rarely have muta-
tions in both EGFR and KRAS. In North America, the
prevalence of these mutations in lung adenocarcinoma is
about 10% and 20%, respectively.
In addition to having predictive value for responses to
EGFR TKIs, EGFR mutations also seem to have prognostic
significance in the advanced or relapsed setting. For example,
in a retrospective subgroup analysis of a clinical trial in which
patients with untreated advanced non-small cell lung cancer
(NSCLC) were randomized to treatment with chemotherapy
plus placebo or chemotherapy plus erlotinib, patients with
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EGFR mutations showed significantly better clinical out-
comes than those with wild-type EGFR in response rate,
time-to-progression, and overall survival, regardless of
whether or not they received erlotinib.7 By contrast, KRAS
mutations did not have prognostic significance. In fact, al-
though there was no difference in time to progression or
overall survival among patients with KRAS mutant versus
wild-type tumors who received chemotherapy alone, patients
with KRAS-mutant tumors who received erlotinib plus che-
motherapy showed poorer clinical outcomes.7
The prognostic value of EGFR and KRAS mutations in
patients with resectable lung adenocarcinoma has not been
established. Some recent studies have compared the survival
of early stage patients with EGFRmutant tumors versus those
with EGFR wild-type tumors and have not found a significant
difference in their overall survival.8–10 However in these
studies, EGFR wild-type tumors were not further classified
by KRAS status. Older studies have shown that patients
harboring a KRAS mutation have a worse overall prognosis
when compared with those with wild-type KRAS.11 A recent
meta-analysis of over 28 studies of RAS mutations in NSCLC
concluded that patients with KRAS mutant tumors have a
significantly worse prognosis, with a combined hazard ratio
1.35 (95% confidence interval [CI] 1.16–1.56).12 However,
KRAS wild-type tumors were not further classified by EGFR
status, as EGFR mutations had not yet been discovered. Here,
we sought to determine the prognostic significance of EGFR
and KRAS mutations in nearly 300 patients who underwent
resection for lung adenocarcinoma. None of the patients
received neoadjuvant or adjuvant EGFR TKI therapy.
PATIENTS AND METHODS
Tissue Procurement
Tumor specimens from patients who underwent surgi-
cal resection at Memorial Sloan-Kettering Cancer Center
(MSKCC) for stage I–III lung adenocarcinoma collected
from January 2002 to February 2006 were obtained with
patients’ consent under an institutional review board (IRB)
approved protocol (#92-055). This protocol exists for fluid
and tissue collection for research purposes only. Patients
were excluded if they had nonadenocarcinoma histology,
stage IV disease, or if they had received treatment with either
gefitinib or erlotinib pre- or post-surgery. Five patients were
excluded due to receiving TKI therapy. Some patients re-
ceived neoadjuvant or adjuvant cytotoxic chemotherapy at
the discretion of their treating physician (Table 1).
All tumors were snap frozen in the operating room in
liquid nitrogen and stored at 80°C. Clinical information
was extracted from IRB approved institutional databases.
Age listed is the age at diagnosis. Stage listed is pathologic
stage after surgical resection according to American Joint
Committee on Cancer guidelines. Smoking status is defined
as never smokers (100 lifetime cigarettes), former smokers
(quit 1 year before diagnosis), or current (quit 1 year
before diagnosis). Internal databases and the Social Security
Death Index (http://ssdi.rootsweb.com/cgi-bin/ssdi.cgi) were
used to determine overall survival. Overall survival was from
date of surgery until death by any cause. Patients without a
date of death were censored at time of last follow-up.
Mutation Detection
DNA was extracted using a kit (DNeasy, Qiagen) or
standard phenol extraction. EGFR mutations were assessed by
direct dideoxynucleotide sequencing of exons 18 to 21,13 poly-
merase chain reaction-based methods that detect exon 19 dele-
tions and exon 21 L858R amino acid substitutions,14 or mass
spectrometry-based genotyping (Sequenom). KRAS mutations
were assessed by direct sequencing of exon 2 or mass spectrom-
etry-based genotyping (Sequenom). Data regarding the mutation
status of some of these tumors was previously reported.13,15,16
Statistical Analysis
Patients were divided into three groups based on mu-
tation type: EGFR mutant, KRAS mutant, or wild type for
EGFR/KRAS. The associations were tested between the clin-
ical characteristics and the mutation groups by using Fisher’s
exact test for the categorical variables. A p value of 0.05
was considered significant.
The Kaplan-Meier method was used to obtain the
survival rates. The log-rank test was used to obtain the
p-values for univariate survival analysis before controlling
TABLE 1. Clinical Characteristics of 296 Patients Whose
Tumors Were Genotyped
EGFR
Mutation
KRAS
Mutation
EGFR/KRAS
Wild-type
pN  40 N  50 N  206
Age 70 (35–86) 70 (42–86) 68 (39–89)
Gender 0.581
Men 14 (35%) 23 (46%) 83 (40%)
Women 26 (65%) 27 (54%) 123 (60%)
Stage 0.064
IA 21 (53%) 16 (32%) 103 (50%)
IB 14 (35%) 14 (28%) 48 (23%)
II 1 (2%) 7 (14%) 21 (10%)
III 4 (10%) 13 (26%) 34 (17%)
Cigarette smoking 0.001
Never 18 (47%) 4 (8%) 14 (5%)
Former 20 (53%) 37 (74%) 154 (83%)
Current 0 9 (18%) 38 (12%)
Chemotherapy 0.405
None 25 (62%) 26 (52%) 128 (62%)
Adjuvant/
neoadjuvant
15 (38%) 24 (48%) 78 (38%)
Mutation
L858R: 19 G12C: 22 N/A
Exon 19 del: 19 G12V: 14
Exon 20 ins: 1 G12A: 7
Exon 21 (H835L): 1 G12D: 6
G13C: 1
Age listed is the mean age. Smoking history is defined as never smokers (100
lifetime cigarettes), former smokers (quit1 year before diagnosis), or current (quit1
year before diagnosis). Note the EGFR exon 20 insertion and exon 21 H835L were not
included in the survival analysis. All p values obtained using Fisher’s exact test and
represent comparisons between the 3 groups.
Del, deletion; ins, insertion.
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for stage; whereas after stage controlling, the stratified log-
rank test was applied to obtain the overall p-values. The
hazard ratios were obtained by using a Cox proportional
hazard model. All p-values were two-sided and a p value
0.05 was considered as statistically significant. The statis-
tical analyses were performed using SAS 9.1 (SAS institute
Inc. Cary, NC) and R 2.5 (http://www.r-project.org).
RESULTS
Two hundred ninety-six resected stage I–III lung ade-
nocarcinomas were genotyped for EGFR kinase domain and
KRAS mutations. Clinical characteristics of patients whose
tumors were examined are listed in Table 1. EGFR and KRAS
mutations were detected in tumors from 40 (14%) and 50
(17%) patients, respectively. No tumor had both mutations.
Two patients with EGFR mutant tumors (Table 1) were
excluded from subsequent survival analyses because they had
rare atypical mutations which are less well studied in terms of
their oncogenic properties and sensitivity to EGFR TKIs.
No differences were observed in the gender distribution
between patients with EGFR mutant, KRAS mutant, or wild-
type tumors (p  0.581). The rates of induction and/or
adjuvant therapy with cytotoxic chemotherapy were also
similar among the three groups of patients (p  0.405, see
Table 1). More patients with EGFR mutation had a history of
never smoking (48% versus 8% with KRASmutations and 5%
with wild type; p  0.001). Patients with KRAS mutant
tumors presented with later stage disease than those with
EGFR mutant tumors (p  0.031) and when compared with
both EGFR mutant and wild-type combined (p  0.064).
Eighty-eight percent of patients with EGFR mutant adeno-
carcinomas presented with stage I disease, whereas 73% of
patients with wild-type tumors and only 60% of patients with
KRAS mutant tumors presented with stage I disease.
With a median time to follow-up of 35 months, the
median overall survival for patients with EGFR mutant,
KRAS mutant, or wild-type tumors for both genes has not yet
been reached. On univariate analysis, patients with EGFR
mutant tumors had a longer overall survival than patients with
KRAS mutant tumors (p  0.009, Figure 1) and versus KRAS
Overall Survival: EGFR and KRAS
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FIGURE 1. Kaplan-Meier survival curves for 88 patients
with an EGFR or KRAS mutant tumor. Unadjusted p  0.009,
stage adjusted p  0.108.
Overall Survival: EGFR vs KRAS vs WildType
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FIGURE 2. Kaplan-Meier survival curves for 294 patients.
The median follow-up time is 35 months. The median sur-
vival was not reached for any group. Unadjusted p  0.031,
stage adjusted p  0.18.
Overall Survival: Exon 19 Deletion vs L858R
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FIGURE 3. Kaplan-Meier survival curves for 38 patients
with either L858R mutation or exon 19 deletion in EGFR. Un-
adjusted p  0.499.
Journal of Thoracic Oncology • Volume 3, Number 2, February 2008 EGFR and KRAS Mutations
Copyright © 2008 by the International Association for the Study of Lung Cancer 113
mutant tumors and EGFR/KRAS wild-type tumors together
(p  0.031, Figure 2). The 3-year overall survival rates for
patients with EGFR mutant, EGFR/KRAS wild type, and
KRAS mutant tumors were 90% (95% CI 70–97%), 76%
(95% CI 69–81%), and 66% (95% CI 48–79%), respec-
tively. There was no difference in survival between those
patients with EGFR L858R versus those with an exon 19
deletion (Figure 3). The overall survival between never and
ever smokers was similar (Figure 4).
After adjustment for pathologic stage, patients whose
tumors harbored EGFR mutations displayed a trend toward
longer survival when compared with patients whose tumors
harbored KRAS mutations alone (p  0.108) and those with
wild-type tumors (p  0.18, Table 2). For stage I disease
only, patients with EGFR mutant tumors showed a trend
toward longer overall survival compared with patients with
KRAS mutant tumors, on both univariate analysis (p  0.11)
and after stage adjustment (p  0.147) (Figure 5).
Overall Survival: Never Smoker vs Ever Smoker
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FIGURE 4. Kaplan-Meier survival curves for ever versus
never smokers. Unadjusted p  0.426, stage adjusted p 
0.586.
Overall Survival: Stage I – EGFR vs KRAS
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FIGURE 5. Kaplan-Meier survival curves for patients with
stage I lung adenocarcinoma: EGFR mutant (n  33), KRAS
mutant (n  30). Unadjusted p  0.11, stage adjusted (IA,
IB) p  0.147.
TABLE 2. Overall Survival Analysis Results for 294 Patients Before and After Adjusting for Stage
Variable Category N
3 yr OS Rate%
(95% CI)
Unadjusted Stage Adjusted
Hazard Ratio
(95% CI) p
Hazard Ratio
(95% CI) p
Stage IA 139 89 (82–93%) Ref. level 0.001 N/A
IB 75 75 (63–84%) 2.9 (1.4–6.0)
II 29 51 (28–70%) 6.8 (3.1–14.9)
III 51 52 (34–68%) 5.5 (2.8–10.9)
Gender F 176 80 (73–86%) Ref. level 0.009 Ref. level 0.043
M 118 69 (59–77%) 1.9 (1.2–3.1) 1.7 (1.0–2.7)
Mutation type Wild type 206 76 (69–81%) Ref. level 0.031 Ref. level 0.18
EGFR 38 90 (70–97%) 0.4 (0.1–1.1) 0.4 (0.1–1.4)
KRAS 50 66 (48–79%) 1.6 (0.9–2.9) 1.3 (0.7–2.4)
EGFR 38 90 (70–97%) Ref. level 0.009 Ref. level 0.108
KRAS 50 66 (48–79%) 4.5 (1.3–15.7) 2.8 (0.8–10.1)
Smoking history Never 36 80 (60–91%) Ref. level 0.426 Ref. level 0.586
Current/former 258 75 (69–81%) 1.4 (0.6–3.3) 1.3 (0.5–3.0)
Never smokers defined as having smoked 100 lifetime cigarettes. All p values are obtained by either using log-rank test for the unadjusted setting or the stratified log-rank test
for the adjusted setting.
OS, overall survival.
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DISCUSSION
Among patients with completely resected NSCLC in
the United States, 30% of stage I, 60% of stage II, and 75%
of stage IIIA patients, respectively, die within 5 years of
resection.17 Adjuvant cisplatin-based chemotherapy has been
shown to increase overall survival.18 A recent meta-analysis
from nearly 5000 patients randomized to either surgery fol-
lowed by cisplatin-based adjuvant chemotherapy or surgery
alone demonstrated that higher stage patients garner more
benefit from adjuvant chemotherapy.19 However, there are no
data to support adjuvant chemotherapy in patients with stage
IA disease, little support for treating stage IB patients, no data
for stage II–III patients who are not candidates for cisplatin,
and no data for patients more than the age of 75.20 Clearly,
better prognostic and predictive biomarkers are needed to
help oncologists decide which patients to treat and which
drugs to use.
Many clinical factors (e.g., age, gender, performance
status, tumor size, pathologic stage, extent of resection, his-
tologic subtype, etc.) have been shown to have prognostic
value in resected NSCLC.21,22 However, although these char-
acteristics can be used to help decide whether patients should
receive adjuvant therapy, none of them predict sensitivity or
resistance to specific types of adjuvant treatment. Recently,
several studies using mRNA profiling of resected lung tumors
have sought further to identify molecular subtypes associated
with patient outcome. Gene expression signatures ranging
from 5 to 64 genes have shown predictive value.23–25 How-
ever, these studies have identified nonoverlapping gene sets
and are not available for widespread use. How many of the
individual genes within these profiles that contribute to tumor
biology is not known. Moreover, whether any chemotherapy
can effectively alter the prognosis defined by a significant
molecular signature remains to be established.
In this study, we examined the prognostic significance
of two genetic alterations in lung adenocarcinoma—EGFR
and KRAS mutations—that already have known biologic and
therapeutic relevance. Both mutations are oncogenic and
importantly, EGFR mutations are associated with benefit
from EGFR TKIs, whereas KRAS mutations predict for re-
sistance to these drugs. In patients with metastatic disease,
EGFR mutations may also have prognostic significance, but
the impact of either mutation on overall survival has not yet
been well studied in patients with resected disease. Others
have examined only the prognostic significance of tumors
mutant versus wild type for EGFR8,10 or KRAS,12,26,27 but not
in direct comparison with one another.
Our analysis of nearly 300 cases of genotyped lung
adenocarcinomas shows that EGFR and KRAS mutations
delineate biologically distinct subsets of lung adenocarci-
noma. In the absence of targeted therapy, patients whose
tumors contain an EGFR mutation had a 90% (95% CI
70–97%) 3-year overall survival compared with a 66% (95%
CI 48–79%) 3-year overall survival for patients with KRAS
mutant tumors. The survival difference approaches signifi-
cance on multivariate analysis even though 40% of the
patients with KRAS mutant tumors presented with stage II or
greater disease, while 88% of the patients with EGFR mutant
tumors presented with stage I disease. The 3-year overall
survival for stage I patients only was 92% (95% CI 70–98%)
for the EGFR mutant group (n  33) and 82% (95% CI
62–92%) for the KRAS mutant group (n  30).
We observed no difference in survival in patients
whose resected tumors harbored the two most common
EGFR mutations (i.e., the L858R mutant or an exon 19
deletion mutant). By contrast, in the metastatic setting, we
previously reported that patients whose tumors harbor exon
19 deletion mutations seem to have a longer overall survival
compared with those with the L858R mutation when treated
with gefitinib or erlotinib.16 If validated in other studies, these
data suggest that existing EGFR TKIs differentially affect the
natural history of patients with EGFR mutant tumors.
We also found no difference in survival between never
versus ever smokers (Figure 4). Several others have reported
that among patients with NSCLC, never smokers have a
better overall survival than ever smokers.28,29 The exclusion
of patients with nonadenocarcinoma histology in this study
could underlie the discrepant results, as most never smokers
who develop lung cancer have tumors with adenocarcinoma
histology. The high percentage of females seen at our insti-
tution and the limited follow-up of largely patients with stage
I disease may also help explain this finding.
This study has several limitations. The data represents
a retrospective review of a cohort of patients seen at a single
academic institution over a period of 4 years. Our physicians
routinely see more women with lung cancer than the national
average and this is reflected in our study population. Also, we
included only patients with adenocarcinoma histology and
those with stage I–III disease who underwent a complete
resection. Other histologic types of NSCLC were excluded
because the frequency of EGFR mutations in nonadenocar-
cinoma NSCLC is so low (1%) that such subtypes are not
routinely tested for EGFR mutations at MSKCC.30 In the
future, we plan to enlarge our sample size and potentially
include other histologic subtypes to better delineate the dif-
ferences that exist between EGFR and KRAS mutant lung
tumors in NSCLC.
Another limitation of the study is sample size. We
studied survival rates of only 294 patients. However, our aim
was to identify any differences between patients with EGFR
and KRAS mutant tumors, and these sample sizes (n 40 and
50, respectively) are comparable with other North American
series.8,31 Approximately another 600 patients would need to
be genotyped and analyzed to validate the survival difference
seen here on univariate analysis between those with EGFR
and KRAS mutant tumors.
Because EGFR and KRAS mutations seem to have both
prognostic and predictive significance, we now routinely
perform mutation testing on all adenocarcinomas resected at
MSKCC. We believe the survival of the subset with EGFR
mutant tumors could in theory be further extended with
EGFR TKIs. Thus, we plan to conduct a single-arm, phase
two clinical trial of erlotinib as adjuvant chemotherapy for
patients whose tumor harbors an EGFR mutation and who
have completed standard adjuvant chemotherapy.
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Conversely, there is presently no targeted therapy ef-
fective for patients with KRAS mutant tumors. A recent
prospective analysis demonstrated that for this subset of
patients, even adjuvant cisplatin-based chemotherapy does
not confer a survival advantage.18 For these individuals, we
plan to conduct a clinical trial involving mutant KRAS-
specific vaccines after noncisplatin-based chemotherapy.32
This study represents the first direct comparison of the
survival of resected patients with either EGFR or KRAS
mutant lung adenocarcinomas compared with those that are
wild type for both genes, in the absence of targeted therapy.
The data indicate further that EGFR and KRAS mutations
define clinically distinct molecular subsets of lung adenocar-
cinoma. Importantly, because EGFR and KRASmutations can
predict sensitivity and resistance, respectively, to EGFR
TKIs, they are important tumor characteristics that can be
readily incorporated into clinical trials to help guide the
administration of specific types of adjuvant therapy.
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